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Abstract
Background:  The nature is a fascinating source of biologic active substances, many of which are showing promising antitumor activities [1, 2].  The 
triterpenes are an important class of phytochemicals, classified in accordance with isoprene units [3, 4].  These chemicals are synthesized by the plants 
through cyclic processing of squalen.  About 20000 of triterpens, such as cucurbitanes, cycloartanes, friedelanes, holostanes, hopanes, lanostanes, lupanes, 
oleananes, dammaranes, euphanes, tirucallanes, isomalabaricanes, ursanes and others are identified at the moment.  From a wide diversity of triterpenes, 
the pentacyclic derivatives were the most frequent studied chemicals, due to their anti-inflammatory, analgesic, hepatoprotective, cardiotonic, anti-
alergic, anti-microbial and anti-tumor properties [5-9].  Ursolic acid or 3β-hydroxi-urs-12-en-28-oic acid is a triterpen’s pentacyclic acid was discovered 
in plants, such as Ocimum sanctum L.(Holy Basil), Prunus laurocerasus L. (Cherry laurel leaves), Vaccinum myrtillus L. (Bilberry), Crataegus laevigata 
(Hawthorn), Harpagophytum procumbens DC (Devil’s Claw), Thymus vulgaris L. (Thyme), Sambucus nigra L. (Elder Flowers), Origanum vulgare L. 
(Oregano), Lavandula augustifolia Mill. (Lavender), Vinca minor L. (Periwinkle), as well as in the wax from apples, plums and pears peels [10].  It is a 
pentacyclic triterpenoid which belongs to cyclosqualenoid family [11].  This acid can be determined free or as aglicon of saponins. The recent results are 
supporting the anti-inflammatory, anti-proliferative, pro-apoptotic, anti-metastatic, anti-angiogenic and anti-parasite functions of this chemical [7,12]. 
The aim of this study was to highlight in details the anti-tumor activity of ursolic acid, by pointing out its influence on cells proliferating, apoptosis and 
metastatic property.
Conclusions: Ursolic acid is a promising compound in tumor prevention and treatment, with many mechanisms of action on cell’s proliferation.  Its 
derivatives usually are more biologically effective than initial compound, so obtaining of new ursolic derivatives makes further investigations in this 
field have a particular relevance.
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Ursolic acid isolation
This chemical was isolated through different methods 
[13].  Generally, plants are extracted by two solvents with 
increasing polarity, hexan and ethyl acetate in Soxhlet.  The 
obtained extract of ethyl acetate is concentrated in rotary 
evaporator.  Until now were purposed many isolation 
methods in organic solvents by using high pressure liquid 
chromatography (HPLC), thin layer chromatography (TLC) 
and gas-chromatography after silylation and methylation 
[14-16].  Kontogianni et al. (2009) have demonstrated that 
combination of 1H-13C HSQC and 1H-13C HMBC NMR 
spectroscopies is a fast analytical method which clarifies 
and quantifies triterpenic acids in plants’ extracts [17]. 
However, today the most frequently used method is bi-
oassay-guided fractionation, based on physico-chemical 
differences.  But this method anyway implies chromato-
graphic techniques. 
Finally, a clean isolated ursolic scid (UA) looks as glossy 
prisms after purification in absolute alcohol or as long thre-
ads, hair-like from diluted alcohol.  The melting point of 
this chemical reaches 284-288 0C.  Ursolic acid is soluble in 
organic solvents such as ethanol, hot glacial acetic acid, in 2% 
alcoholic NaOH, dimethyl sulfoxide and dimethyl formamide, 
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which should be purged with an inert gas.  It is insoluble in 
water (fig. 1).
Antitumor activity of ursolic acid
Multiple studies have confirmed that tumor progression 
is stimulated by pro-inflammatory factors: nuclear factor 
NF-kB, transcriptor activator 3 (STAT3), protein kinase B 
(AKT), cyclooxygenase-2 (COX-2) [18-20] among them.  All 
these factors showed a pro-tumor activity, by stimulating cell 
proliferation, angiogenesis and metastatic properties. 
Nuclear factor NF-kB is a regulating key implicated almost 
in all cell’s processes [22].  Activation of this factor is often 
associated with chronic inflammation, tumorigenesys and 
resistance to chemo/radiotherapy [22, 23].  Many studies in 
the field support the role of chronic inflammation in tumor 
formation. Its presence is represented as a high risk in cancer 
development.  Oeckinghaus et al. (2011) demonstrated that 
phosphorylation of IkB proteins by IkB kinases is a key process 
finalized with NF-kB coupling DNA and transcription acti-
vation of certain genes [24].  Until now have been purposed 
many agents targeted at this mechanism [7, 25].  Studies in 
vitro demonstrated the UA ability to block NF-kB activation 
induced by carcinogenic agents, such as TNF, okadaic acid, 
H2O2 and tobacco smock. By Shishodia et al.  (2003) this 
action of UA is realized through IkBα kinases suppression 
and blocking of p65/Re1A phosphorilation [26].  Authors 
have reported that NF-kB inhibition was supplemented and 
by NF-KB dependent enzymes blocking, as cyclin D1, COX-2 
and MMP-9 (matrix metalloproteinase-9).
Ursolic acid showed a promising activity against multiple 
types of tumors.  Pathak et al. (2007) demonstrated a cytos-
tatic activity of UA in case of multiple myeloma [27].  This 
action was realized through suppression of a wide series of 
kinases, such as c-SRC, Janus-activated kinases 1 and 2 (JAK 
½ kinases). Doudican et al. (2014) by using a predictive si-
mulation technology demonstrated that UA is very effective 
in case of multiple myeloma, especially in combination with 
other anti-cancer agents, such as pan-JNK inhibitor SP600125 
[28].  Authors showed that such combination synergistically 
inhibited proliferation and induced apoptosis, evidenced by 
an increase in the percentage sub-G1 phase cells, cleavage of 
caspase 3 and poly-ADP-ribose-polymerase, as well a signi-
ficant reduction in the expression of cyclin D1 and c-Myc.
Fig. 1.  Chemical structure of ursolic acid.
Recently, Shanmugam et al. (2011) examined UA action 
on prostate carcinoma cell lines.  This chemical was effective 
in androgen-independent tumors (DU145), as well andro-
gen-dependent (LNCaP) [29].  This action was realized by 
suppression of genes regulated by STAT3 and NF-kB [30]. 
More, Shin et al. (2012) demonstrated that this triterpene 
has a stimulatory effect on LC3-II (microtubule-associated 
protein 1A/1B-light chain 3) resulted with activation of auto-
phagy process in PC3 cells [31].  Zhang et al. (2010) consider 
that UA is beneficial in prostate cancer by its implication in 
signaling pathway mediated PI3/Akt/mTOR and Beclin-1, 
finally stimulating apoptosis [32]. 
Wang et al. (2011) tested UA and its cis-, trans-3-O-p-
hydroxycinnamoyl derivatives on prostatic cells clone DU145 
[33].  Authors presented an increased inhibitory capacity of 
UA on metalloproteinases MMP-2 and MMP-9.
Ursolic acid showed anti-tumor effect and in vivo experi-
ments. Shanmugam et al. (2012) tested UA action during 4-36 
weeks on mice with DU145 cells implant and with a transgenic 
prostate adenocarcinoma [7, 34].  Authors demonstrated that 
UA had an inhibitory action on tumor progression after 8 
weeks of UA administration, effect supplemented at 12 weeks 
with a significant tumor size diminishing.  Therewith UA in-
hibited in prostate a series of pro-inflammatory mediators, as 
NF-kB, STAT3, IKK α/β and AKT. Systemic effect of UA was 
expressed by diminishing the TNFα (tumor necrosis factor 
alpha, cachexin or cachectin) and IL-6 (interleukin 6) levels 
in peripheral blood. 
In accordance with data reported by Teicher et al. (2010), 
UA has ability to block metastasis development [35].  The 
mechanisms of action suppose blocking signaling pathway 
CXCR4/CXCL12 (C-X-C chemokine receptor type 4/C-X-C 
motif chemokine 12).  In Shanmugam et al. (2011) opinion 
this acid can suppress expression of CXCR4 in prostatic tumor 
cells, regardless of HER2 (human epidermal growth factor 
receptor 2) status [30].  Therewith authors support the impli-
cation of this natural compound in transcription regulation 
and blocking of NF-kB activation. 
The anti-proliferative effect of UA was confirmed by Zheng 
et al. (2012) on T24 urinary bladder cancer cells line [36]. 
Authors confirmed that UA can induce organization of an in-
tracellular signaling complex IRE1-TRAF2-ASK1 (the serine/
threonine-protein kinase/endoribonuclease inositol-requiring 
enzyme 1- TNF receptor-associated factor 2- Apoptosis signal-
regulating kinase 1) with pro-apoptotic function. 
In accordance with data published by Liu et al. (2012) this 
triterpene has capacity to improve bronchial epithelium status 
affected by tobacco extract.  More is a promising prophylactic 
agent able to prevent pulmonary cancer development [37]. 
Huang’s et al. (2011) results demonstrated that UA can induce 
apoptosis in tumor cells A549, H3255 and Calu-6 [38]. 
Lung cancer is one the most frequent tumor among smo-
kers [39].  Ursolic acid demonstrated its activity in treating 
this cancer by blocking invasive properties of series of tumor 
clones as A549, H3255 and Calu-6. Moreover, this triterpene 
was able to initiate apoptosis in cancer cells at quite small 
dosage, of 2µmol/L [38, 40].
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Prasad et al. (2012) presented results which denote the 
efficacy of UA in colorectal cancer [41].  In authors opinion, 
pro-apoptotic effect is realized by NF-kB inhibition and 
suppression of proteins with anti-apoptotic function (cFlip 
(FLICE-like inhibitory protein), survivin, Bcl-2 (B-cell lym-
phoma 2), Bcl-xl (B-cell lymphoma-extra large)), prolifera-
tive (cyclin D1) and pro-metastatic (ICAM-1 (Intercellular 
Adhesion Molecule 1), VEGF (vascular endothelial growth 
factor), MMP-9 (Matrix metallopeptidase 9)).  This chemical 
at digestive tract level could stop growing and induce apop-
tosis in pancreatic tumor cells (PANC-1 (human pancreatic 
carcinoma, epithelial-like cell line), CAPAN-1 (human pan-
creatic ductal adenocarcinoma cell line)).  In opinion of Li et 
al. (2012) this action is realized through UA implication in 
signaling pathways JNK and PI3K/Akt/NF-kB [42]. 
The anti-tumor activity of UA was demonstrated in vivo mo-
use models of colorectal cancer [41].  Prasad et al. (2012) reported 
a considerable decreasing of tumor, ascites, as well diminishing 
of metastatic properties of cancer cells.  Authors support that 
UA realizes this activity through inhibition of Ki-67 marker of 
proliferation and CD31.  These effects were attended by NF-kB, 
STAT3 and β-catenin suppression.  Andersson et al. (2008) have 
reported a diminishing of aberrant crypts in colorectal adenoma, 
after UA oral administration [43].
Ursolic acid presented a promising action in vitro ex-
periment on K562 clone of leukemia cells. Wu et al. (2012) 
have demonstrated that UA induces apoptosis by stimulating 
PTEN (Phosphatase and tensin homolog) expression, block-
ing activation of Akt kinases, alteration of mitochondrial 
membrane potential, reducing of cytochrome C releasing, 
stimulating a series of caspases [44].  These data were sup-
plemented by Zhang et al. (2011) who consider that UA can 
induce differentiation of HL60 promyelocytic leukemia cells 
to monocytes and stimulate expression of CEBPβ (CCAAT/
enhancer-binding protein beta) [45].  Gao et al. (2012) presen-
ted promising results in vivo experiments [46]. Ursolic acid, 
50 mg/kg administrated 20 days to NOD/SCID mice with 
U937 implant concluded with impressive blocking of tumor 
proliferation.  These results are in line with Chiang et al. (2003) 
data, which reported that UA is very effective against P3HR1 
cells (2.5 µg/ml) and human immortalised myelogenous le-
ukemia line K562 (17.79 µg/ml) [47].  Lauthier et al. (2000) 
demonstrated that ursolic acid can decrease cell viability in 
human lymphoma Daudi cells (human Burkitt’s lymphoma 
cell line) in a dose-dependent manner [48].  Authors showed 
that UA also induced morphological changes in cells such as 
loss of membrane asymmetry, DNA fragmentation and nuclei 
condensation. In their opinion these changes indicating that 
the mechanism by which UA induced cell death was through 
apoptosis.  More, authors hypothesized that the binding of UA 
to glucocorticoid receptors and the Ca2+ currents constituted 
the first steps of apoptosis. Ovesná et al. (2006) investigated 
protective effects of UA against H2O2 -induced DNA dama-
ge in leukemic L1210, K562 and HL-60 cells [49].  Authors 
demonstrated that after 24h pre-treatment of cells with UA 
(2.5-10µmol/l) the incidence of DNA single strand breaks 
induced by H2O2 decreased significantly.
In mammary carcinoma cells MDA-MB-231 this triterpe-
ne initiated apoptosis by stimulating Fas receptor, cleavage of 
caspases 3, 8 and PARP (Poly (ADP-ribose) polymerase), stimu-
lating pro-apoptotic protein Bax and releasing of cytocrome 
C from mitochondrion in cytoplasm, blocking anti-apoptotic 
BCL-2 receptor [50].  Subbaramiah et al. (2000) investigated 
the influence of UA on COX-2 expression in mammary cells 
treated with PMA (phorbol 12-myristate 13-acetate) [51]. 
The results attested a long-standing blockage of COX-2, 
protein-kinases C, c-Jun N-terminal kinases, inhibition of 
prostaglandin E2 synthesis.  An antitumor action presented 
and UA derivative, 2α-hydroxiursolic acid.  This one could 
block tumor cells MCF-7 proliferation at 20µM concentration, 
function realized through TNF-α and NF-kB [52].  Plus, De 
Angel et al. (2010) presented a promising result of UA action 
on C57BL/6 mice, ovariectomized with transgenic breast 
carcinoma [53].  Ursolic acid administered during 5 weeks 
resulted in a significant diminishing of tumor size, effect 
in authors’ opinion exercised by UA involvement in Akt/
mTOR signaling pathway and apoptosis inducing.  But, this 
results are contested by Singletary et al. (1996), who did not 
establish any therapeutic effects after UA administration to 
the rats with breast tumors induced by 7,12-dimethyl-benz(a)-
antracene [54].
A promising, anti-angiogenic action of UA was described 
after its testing on hepatic cancer cells, as Hep3B, Huh7 and 
HA22T.  Lin et al. (2011) consider, that this function is realized 
by inhibition of a series of factors, such as HIF-1α (hypoxia 
inducible factor-1α), bFGF (basic fibroblast growth factor), 
VEGF (Vascular endothelial growth factor), interleukin 8, 
urokinazic plasminogen activator (uPA), supplemented by 
diminishing the levels of reactive oxygen (ROS) and nitric 
oxide (NO) [55].  Tian et al. (2006) reported that UA has 
ability to block both hepatic tumor cells HepG2 and their 
derivatives R-HepG2, resistant to chemotherapy, supple-
mented by a minor inhibitory effect on normal hepatocites 
[56].  Authors also demonstrated that COX-2 blocking and 
HSP (heat shock protein) stimulating, correlated with apop-
tosis enhance in HepG2 cells.  This, pro-apoptotic effect was 
further determined on other hepatic tumor cells, such as 
Hep3B, Huh7 and HA22T.  But this action was dependent on 
UA concentration: at high dosage a DNA fragmentation and 
cells’ viability decreasing was attested.  Similar results were 
reported by Ramos et al. (2008), who consider that ursolic acid 
can prevent DNA damage and has antiproliferative properties 
applied on HepG2 cells [57].
In accordance with results reported by Yan et al. (2010), 
treating of hepatic tumor cell with UA lead to Na+, K+-
ATP-ase blocking and VEGF reduction [58].  Gayathri et al. 
(2000) have investigated COX-2 expression in mammary cells, 
treated with phorbol (PMA), a carcinogenic agent (phorbol 
12-myristate 13-acetate).  Ursolic acid suppressed effectively 
the PMA action by blocking COX-2 protein and diminution 
of E2 prostaglandin synthesis.  Likewise, the tumorigenic 
action of PMA was diminished by blockage of a series of 
kinases, such protein kinase C, c-Jun-N-terminal-kinase 
and proten kinase p38 mitogen activated.  Administration of 
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20 mg/kg UA per os during 6 weeks resulted in a significant 
reducing of oxidative stress markers in hepatic cancer DENA 
(diethylnitrosamine) induced to Wistar rats [59].  In accor-
dance with authors’ opinion, these data support the UA role 
as prophylactic drug in cancer prevention.  The UA activity 
was examined also in vivo on hepatic tumor H22 [60].  Shao 
et al. (2011) demonstrated that UA usage at 100 mg/kg could 
lead to a significant inhibition of tumor growing. 
A promising result of UA action was reported and in case 
of neural origin tumor.  Wang et al. (2012) studied the behavior 
of glioma cells U251 after treating with this triterpene [61]. 
Authors realized that UA activated caspase-3 and suppressed 
miR-21(microRNA-21) at concentrations of 5-20 µM.  The 
final effect was expressed by blocking tumor cells proliferation 
and apoptosis inducing. 
The wide chain of UA function is supplemented by 
Tokuda’s et al. (1986) research on skin tumors induced by TPA 
(tetradecanoyl-phorbol-13-acetate) [62].  Authors concluded 
that this triterpene could inhibit tumors growing, in a manner 
similar to retinoic acid, well-known for its anti-tumor activity. 
Kowalczyk et al. (2009) reported that UA is a very effective 
agent to prevent skin cancer, because it can block mutation 
occurrence in 61 codon of Ha-ras oncogene [63].
The ursolic acid utilization to prevent 
chemoresistance development
The resistance developed by the tumors to specific therapy, 
chemo or radio, is one of the main reasons of recurrences and 
neoplastic progression.  In drug resistance development were 
involved a series of MDR mediators (multi-drug resistance 
proteins), as well factors with anti-apoptotic function [64]. 
Shan et al. (2011) demonstrated that UA has ability to block 
MDR proteins in case of intestine tumor clones (SW480, 
SW620), leukemia cells HL60, HL60/ADR, K562, K562/
ADR and breast carcinoma cell lines (MCF7 și MCF7/ADR) 
[48].  Moreover, this compound was very effective and in case 
of very aggressive HepG2, doxorubicin-resistant clones [65]. 
The biological activity  
of ursolic acid derivatives
A promising biological activity manifest and UA derivati-
ves, frequently more emphasized as incipient chemicals.  As 
we mentioned above, a remarkable anti-proliferative effect 
demonstrated 2α-hydroxyursolic acid in breast carcinoma cell 
lines [52].  A series of new derivatives were synthesized on acyl 
piperazin base.  In accordance with Liu et al. (2012) opinion, 
these chemicals showed an inhibitory action significantly 
higher than clean UA in case of gastric carcinoma cells (MGC-
803) and breast cancer (Bcap-37) [66].  These results are a 
confirmation of previous data published by Ma et al. (2005), 
who highlighted the cytotoxic activity of 2α-hydroxyursolic 
acid on 4 tumor cell lines, as HL-60 (human promyelocytic 
leukemia cells), BGC (gastric cell line), Bel-7402 (hepatic 
carcinoma cell line) and HeLa (cervical cancer cell line) [67]. 
The recent presentation of Chen et al. (2011) argues the 
development of new derivatives of UA [68].  Authors de-
monstrated that UA derivatives obtained on the furoxan (or 
1,2,5-oxadiazole 2-oxide) base have a higher cytotoxic poten-
tial than native chemical, applied on HepG2 tumors. Tanaka 
et al. (2012) support the idea that UA derivatives obtained 
through oxidation with dioxoruthenium-VI- tetraphenyl-
porphyrine had an enhanced cytotoxicity (in comparison to 
UA) on glioma C6 and skin carcinoma A431 cell lines [69].
A new possibility of UA derivatives obtaining was re-
cently presented by Leipold et al. (2010) [70].  Authors have 
metabolized UA with 3 clones of gram-positive Nocardia 
bacteria (NRRL 44000, 44822 and 5646).  As a result of these 
biotechnological assays, researches obtained a mixture of UA 
derivatives: ursolic acid methyl ester, ursonic acid, ursonic 
acid methyl ester, 3-oxoursa-1,12-dien-28-oic acid and its 
methyl ester.  The acetylating of UA at C-3 position, combined 
with amino alcohol acetate coupling at C-28 had increased 
significantly its anti-proliferative activity.  In accordance with 
Meng et al. (2009) these compounds were very effectively 
applied on different tumor cell lines, such as HeLa, SKOV3 
and BGC-823 [71]. 
A recent study presented by Bai et al. (2012) emphasizes 2 
groups of UA derivatives, in accordance with their electrical 
properties: group I, negatively charged and group II, with 
positive charge [72].  These derivatives had ability to block 
cell cycle and stimulate apoptosis in several tumor cell lines: 
HepG2, AGS, HT-29 and PC-3.  It is necessary to mention that 
cytotoxic effect of group II was more pronounced than group 
I and UA.  Plus, authors synthesized 3β-acetoxy-urs-12-en-
28-oyl-1-mono-glicerid derivative, able to induce apoptosis 
in BGC-823 cells [73].
Shao et al. (2011) tested another UA derivative, N-[3β-
acetoxy-urs-12-en-28-oyl]-2-aminodiethanol [60].  This com-
pound showed remarkable pro-apoptotic activities applied on 
HepG2, BGC-823, SH-SY5Y, HeLa and HELF tumor cells. 
Promising effects demonstrated heterocyclic derivatives 
of UA, obtained by Leal et al. (2012) [74].  New compounds 
could induce the p53, p21waf1 and NOXA synthesis, effects 
summarized as anti-proliferative activity in pancreatic carci-
noma cells AsPC-1. 
An innovative method was purposed by Zhang et al. 
(2013), which consists in using nanoparticles UA charged 
(UA-NPs) [75].  In their assays, authors transported effec-
tively this complex into gastric carcinoma cells SGC-7901. 
The results pointed out a strong inhibition of COX-2 and 
caspase-3 activation, effects which lead to apoptosis and 
cytotoxicity.
Conclusion: ursolic acid is a promising compound in 
tumor prevention and treatment, with many mechanisms of 
action on cell’s proliferation.  Its derivatives usually are more 
biologically effective than initial compound, so obtaining of 
new ursolic derivatives makes further investigations in this 
field have a particular relevance.
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